Abstract
BackgroundEsophageal adenocarcinoma (EAC) remains a leading cause of cancer-related deaths worldwide, and demonstrates a predominant rising incidence in Western countries. Recently, immunotherapy has dramatically changed the landscape of treatment for many advanced cancers, the benefit in EAC thus far been limited to a small fraction of patients. MethodsUsing somatic mutations data of The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC), we delineated somatic mutation landscape of EAC patients from US and England. Bioinformatics algorithms were utilized to perform function annotation, immune cell infiltration analysis, and immunotherapy response assessment.ResultsWe found that RYR2 was a common frequently mutated gene (FMG) in both cohorts, and patients with RYR2 mutation suggested higher tumor mutation burden (TMB), better prognosis, and superior expression of immune checkpoints. Moreover, RYR2 mutation upregulated the signaling pathways implicated in immune response and enhanced antitumor immunity in EAC. Multiple bioinformatics algorithms for assessing immunotherapy response demonstrated that patients with RYR2 mutation might benefit more from immunotherapy. In order to provide additional reference for antitumor therapy of different RYR2 status, we identified nine latent antitumor drugs associated with RYR2 status in EAC. ConclusionsThis study reveals a novel gene whose mutation could be served as a potential biomarker for prognosis, TMB, and immunotherapy of EAC patients.
Mining The Cancer Genome Atlas database for tumor mutation burden and its clinical implications in gastric cancer
